+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia

Journal of Lipid Research 56(12): 2381-2392

The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (-41%), remnant cholesterol (-55%), and LDL-cholesterol (-39%), with minor effect on HDL-cholesterol (+4%). Lipidomic analysis, normalized to nonHDL-cholesterol in order to probe statin-induced differences in molecular composition independently of reduction in plasma cholesterol, revealed increment in 132 of 138 lipid species that were subnormal at baseline and significantly shifted toward the control group on statin treatment. Increment in alkyl- and alkenylphospholipids (plasmalogens) was prominent, and consistent with significant statin-induced increase in plasma polyunsaturated fatty acid levels. Comparison of the statin-mediated lipidomic changes in MetS with the abnormal plasma lipidomic profile characteristic of prediabetes and T2D in the Australian Diabetes, Obesity, and Lifestyle Study and San Antonio Family Heart Study cohorts by hypergeometric analysis revealed a significant shift toward the lipid profile of controls, indicative of a marked trend toward a normolipidemic phenotype. Pitavastatin attenuated the abnormal plasma lipidome of MetS patients typical of prediabetes and T2D.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058900361

Download citation: RISBibTeXText

PMID: 26486974

DOI: 10.1194/jlr.p061143

Related references

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. Journal of Lipid Research 57(11): 2073-2087, 2016

Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular Therapeutics 32(4): 139-146, 2014

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal 68(5): 646-654, 2016

New insights into statin action on the dyslipidemia of type 2 diabetes: normalisation of the plasma lipid profile. Atherosclerosis 235(2): E106-E107, 2014

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. International Journal of Cardiology 248: 355-360, 2017

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. Journal of Clinical Lipidology 12(3): 784-800.E4, 2018

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy. Clinica e Investigacion en Arteriosclerosis 28(2): 87-93, 2017

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26(12): 2833-2839, 2010

Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. Journal of Cardiology 74(3): 290-295, 2019

What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin. Vnitrni Lekarstvi 61(11): 971-975, 2015

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular Health and Risk Management 6: 351-362, 2010

Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. American Journal of Cardiology 102(8): 1040-1045, 2008

A potential novel therapeutic addition to statin therapy for dyslipidemia. Current Atherosclerosis Reports 13(1): 9, 2011

Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy. American Journal of Cardiology 104(12): 1695-1696, 2009